[
  {
    "id": "1",
    "question": "EC50",
    "answer": "Efficacy-Concentration 50: drug concentration that produces 50% of its maximum effect.",
    "links": ["10", "14", "16"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "2",
    "question": "Clearance",
    "answer": "Drug elimination efficiency.",
    "links": ["13"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "3",
    "question": "Volume of Distribution (Vd)",
    "answer": "Total amount of drug in the body divided by the concentration in the bloodstream. High Vd suggests the drug is distributed widely throughout the body. Lower Vd indicates the drug is mostly confined to the blood plasma.",
    "links": ["13"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "4",
    "question": "Common Development Endpoints",
    "answer": "[1] Overall survival of patients (traditional endpoint). [2] Progression free survival — time patient lives with disease without it worsening. [3] Durable complete response — complete disappearance of all cancer. [4] Palliation — reduction in tumor symptoms.",
    "links": ["8"],
    "subtopic": "Drug Development"
  },
  {
    "id": "5",
    "question": "LD50",
    "answer": "Lethal Dose 50: dosage of the drug where 50% do not survive.",
    "links": ["16"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "6",
    "question": "CFR",
    "answer": "Code of Federal Regulations. All FDA guidelines and policies are codified in CFR Title 21.",
    "links": ["8", "16", "17", "31"],
    "subtopic": "Drug Development"
  },
  {
    "id": "7",
    "question": "DDI Studies",
    "answer": "Drug-drug Interaction Studies: what happens taking other drugs w/ this new drug? Context: Post-Marketing Studies.",
    "links": ["29"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "8",
    "question": "Drug Development",
    "answer": "[1] Preclinical (IND). [2] Phase 1 (toxicity). [3] Phase 2 (efficacy). [4] Phase 3 (endpoints). [5] FDA Approval (NDA). [6] Post-Marketing Studies (EHR).",
    "links": ["4", "6", "16", "17", "51", "56"],
    "subtopic": "Drug Development"
  },
  {
    "id": "9",
    "question": "ADME",
    "answer": "Absorption, Distribution, Metabolism, Excretion.",
    "links": ["11", "13"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "10",
    "question": "Potency",
    "answer": "The amount of drug needed to produce a specific effect. It's a measure of the drug's power.",
    "links": ["1", "14", "51"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "11",
    "question": "Preferred Administration Methods",
    "answer": "Primary: Oral. Secondary: IV.",
    "links": ["9"],
    "subtopic": "Drug Development"
  },
  {
    "id": "12",
    "question": "Therapeutic Window",
    "answer": "On a concentration vs time graph, therapeutic window is the concentration between efficacy (low end) and toxicity (high end). Small therapeutic windows require more careful dosing.",
    "links": ["14"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "13",
    "question": "PK",
    "answer": "Pharmacokinetics: what the body does to the drug.",
    "links": ["2", "3", "9", "14", "15", "18", "20", "32"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "14",
    "question": "PD",
    "answer": "Pharmacodynamics: what the drug does to the body.",
    "links": ["1", "10", "12", "13", "19"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "15",
    "question": "Cmax",
    "answer": "Maximum concentration.",
    "links": ["13"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "16",
    "question": "IND",
    "answer": "Investigational New Drug. Required to begin clinical trials. Submitted after pre-clinical phase.",
    "links": ["1", "5", "6", "8"],
    "subtopic": "Drug Development"
  },
  {
    "id": "17",
    "question": "NDA",
    "answer": "New Drug Application. Required for FDA approval. Submitted after Phase III.",
    "links": ["6", "8"],
    "subtopic": "Drug Development"
  },
  {
    "id": "18",
    "question": "Tmax",
    "answer": "Maximum time.",
    "links": ["13"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "19",
    "question": "Emax",
    "answer": "Maximum Efficacy. Example forms of measurement: reduction in tumor size %",
    "links": ["14"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "20",
    "question": "Half Life",
    "answer": "The time it takes for the drug concentration to decrease to half of its initial amount in the body.",
    "links": ["13"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "21",
    "question": "VM",
    "answer": "Virtual Machine: a technology that can be used to create isolated computing environments, which can be beneficial for some HPC tasks.",
    "links": ["27"],
    "subtopic": "Computing"
  },
  {
    "id": "22",
    "question": "HPC",
    "answer": "High Performance Computing: focused on achieving high performance through parallel processing, often using specialized in-house hardware and infrastructure.",
    "links": ["26", "27"],
    "subtopic": "Computing"
  },
  {
    "id": "23",
    "question": "Cloud Computing",
    "answer": "The practice of using a network of remote servers hosted on the internet to store, manage, and process data, rather than a local server or a personal computer.",
    "links": ["26", "27"],
    "subtopic": "Computing"
  },
  {
    "id": "24",
    "question": "PHI",
    "answer": "Protected Health Information: inherently identifiable information that requires an IRB",
    "links": ["29", "31"],
    "subtopic": "Data"
  },
  {
    "id": "25",
    "question": "DeID OMOP",
    "answer": "Observational Medical Outcomes Partnership: global, open-source community data standard designed to standardize the structure and content of observational data and to enable efficient analyses that can produce reliable evidence.",
    "links": ["30"],
    "subtopic": "Data"
  },
  {
    "id": "26",
    "question": "AWS",
    "answer": "Amazon Web Services: cloud-based HPC platform (cloud computing).",
    "links": ["22", "23"],
    "subtopic": "Computing"
  },
  {
    "id": "27",
    "question": "IC",
    "answer": "Information Commons: a physical or virtual space designed to provide integrated access to information resources, technology, and support services, often within an academic library or educational setting. Includes: data, computation, tools, and community.",
    "links": ["21", "22", "23", "28", "29"],
    "subtopic": "Computing"
  },
  {
    "id": "28",
    "question": "Clinical Concepts",
    "answer": "Extraction of all concepts in clinical notes into structured “clinical concepts”. Example extractions: dosage, ontologies, etc.",
    "links": ["27"],
    "subtopic": "Data"
  },
  {
    "id": "29",
    "question": "EHR",
    "answer": "Electronic Health Records.",
    "links": ["7", "24", "27", "30"],
    "subtopic": "Data"
  },
  {
    "id": "30",
    "question": "DeID",
    "answer": "De-identified Information: names, images, birthdays, etc are all altered or removed for anonymity.",
    "links": ["25", "29"],
    "subtopic": "Data"
  },
  {
    "id": "31",
    "question": "IRB",
    "answer": "Institutional Review Board: a committee that reviews and approves research involving human subjects to ensure ethical and safe practices.",
    "links": ["6", "24"],
    "subtopic": "Data"
  },
  {
    "id": "32",
    "question": "AUC",
    "answer": "Area Under the Curve: measures the area under the ROC curve. An AUC value of 1.0 indicates perfect performance while 0.5 suggests it is random guessing.",
    "links": ["13", "33", "47"],
    "subtopic": "Metrics"
  },
  {
    "id": "33",
    "question": "ROC Curve",
    "answer": "Used to evaluate the performance of a binary classifier by plotting TPR (y) vs. FPR (x) at various classification thresholds (ex. return True if >0.9 vs just >0.5). The model is classifying well if TPR is high and FPR is low in general (at a low enough threshold, TPR and FPR will be 100%). It represents the trade-off between the sensitivity and specificity of a classifier.",
    "links": ["32", "34", "35", "36", "37"],
    "subtopic": "Metrics"
  },
  {
    "id": "34",
    "question": "TPR",
    "answer": "True Positive Rate: of all actual positives, how many caught? Also known as Sensitivity or Recall.",
    "links": ["33", "36", "38"],
    "subtopic": "Metrics"
  },
  {
    "id": "35",
    "question": "FPR",
    "answer": "False Positive Rate: of all actual negatives, how many missed? FPR = FP / (FP + TN)",
    "links": ["33"],
    "subtopic": "Metrics"
  },
  {
    "id": "36",
    "question": "Sensitivity",
    "answer": "Of all actual positives, how many caught? Also known as TPR or Recall.",
    "links": ["33", "34", "38"],
    "subtopic": "Metrics"
  },
  {
    "id": "37",
    "question": "Specificity",
    "answer": "Of all actual negatives, how many caught? Goal: avoid false positives (like precision, but different strategy). Calculated as 1 - FPR = TN / (TN + FP).",
    "links": ["33"],
    "subtopic": "Metrics"
  },
  {
    "id": "38",
    "question": "Recall",
    "answer": "Of all actual positives, how many caught? Goal: Don’t miss any true cases. High recall = few false negatives. Formula: TP / [TP + FN].",
    "links": ["34", "36", "47"],
    "subtopic": "Metrics"
  },
  {
    "id": "39",
    "question": "Precision",
    "answer": "Of all positive reports, how many correct? Goal: Don’t make false claims. High precision = few false positives. Formula: TP / [TP + FP].",
    "links": ["47"],
    "subtopic": "Metrics"
  },
  {
    "id": "40",
    "question": "Supervised Learning",
    "answer": "Utilizes labeled data. Give the model a starting point and end point (labeled data) and the algorithm infers the rules.",
    "links": ["42", "44", "46", "47"],
    "subtopic": "Statistics"
  },
  {
    "id": "41",
    "question": "Unsupervised Learning",
    "answer": "Utilizes unlabeled data. Without labels, model finds hidden patterns on its own. During evaluation, you need to have a strong understanding of what you are looking for (since there is no labeled data).",
    "links": ["42", "43"],
    "subtopic": "Statistics"
  },
  {
    "id": "42",
    "question": "Semi-supervised Learning",
    "answer": "Learning from limited labels. Leverage unlabeled data to improve models trained on limited labeled data.",
    "links": ["40", "41"],
    "subtopic": "Statistics"
  },
  {
    "id": "43",
    "question": "Dimensionality Reduction",
    "answer": "Goal: reduce number of input variables while preserving as much meaningful structure or variance as possible in order to: [1] simplify model, [2] improve performance, [3] reduce overfitting.",
    "links": ["41", "48", "49", "50"],
    "subtopic": "Statistics"
  },
  {
    "id": "44",
    "question": "Feature Importance",
    "answer": "Transform raw data into meaningful “features” - numerical representations (vectorization).",
    "links": ["40"],
    "subtopic": "Statistics"
  },
  {
    "id": "45",
    "question": "Accuracy",
    "answer": "(TP + TN) / (TP + FP + TN + FN)",
    "links": ["47"],
    "subtopic": "Metrics"
  },
  {
    "id": "46",
    "question": "Regression",
    "answer": "Predict continuous numerical value.",
    "links": ["40", "62", "63", "64", "65", "67"],
    "subtopic": "Statistics"
  },
  {
    "id": "47",
    "question": "Classification",
    "answer": "Predict a category or class.",
    "links": ["32", "38", "39", "40", "45", "66", "68"],
    "subtopic": "Statistics"
  },
  {
    "id": "48",
    "question": "PCA",
    "answer": "Dimensionality Reduction Technique: linear, fast, interpretable.",
    "links": ["43"],
    "subtopic": "Statistics"
  },
  {
    "id": "49",
    "question": "UMAP",
    "answer": "Dimensionality Reduction Technique: nonlinear, preserves local and global structure. Great for visualization.",
    "links": ["43"],
    "subtopic": "Statistics"
  },
  {
    "id": "50",
    "question": "t-SNE",
    "answer": "Dimensionality Reduction Technique: good for visualizing 2D/3D high-dimensional data.",
    "links": ["43"],
    "subtopic": "Statistics"
  },
  {
    "id": "51",
    "question": "Drug Discovery",
    "answer": "Goal: give us a lead therapeutic candidate.",
    "links": ["8", "10", "52", "53", "54", "55", "58", "59", "60", "61"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "52",
    "question": "Biologics",
    "answer": "Larger, more complex therapeutics derived from living organisms or their cells and usually administered by injection or infusion.",
    "links": ["51", "57"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "53",
    "question": "Small Molecules",
    "answer": "Typically chemically synthesized, relatively small, and often orally bioavailable.",
    "links": ["51"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "54",
    "question": "Agonist",
    "answer": "Binds to a receptor and activates it, producing a biological response.",
    "links": ["51"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "55",
    "question": "Antagonist",
    "answer": "Binds to a receptor, but does not activate it, instead blocking the receptor and preventing other molecules from binding and activating it.",
    "links": ["51"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "56",
    "question": "Humanization",
    "answer": "The process of modifying laboratory mice so that they more closely resemble humans, primarily in their immune system or other biological systems. This involves introducing human genes, cells, or tissues into the mice, allowing researchers to study human-specific diseases and therapies in a more relevant preclinical model.",
    "links": ["8"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "57",
    "question": "Antibodies",
    "answer": "Made up of two polypeptides (light chains) and a dimer (heavy chains). The variable regions of the heavy and light chains (VH and VL) form the antigen-binding sites, allowing antibodies to specifically recognize and bind to antigens. The constant regions of the heavy chains (CH1, CH2, CH3, and sometimes CH4) determine the antibody's class and interact with effector cells and molecules.",
    "links": ["52"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "58",
    "question": "Affinity",
    "answer": "The strength with which a ligand binds to its receptor (a receptor with high affinity will bind to ligands even when their concentration is low).",
    "links": ["51"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "59",
    "question": "Saturation",
    "answer": "The degree to which receptors are occupied by messengers. There are only so many receptors available to bind messengers – eventually they may all be “in use”!",
    "links": ["51"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "60",
    "question": "Specificity (binding)",
    "answer": "The ability of a ligand to bind to one type of receptor; a messenger will only bind to a cell with the correct receptor.",
    "links": ["51"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "61",
    "question": "Competition",
    "answer": "The ability of different ligands to compete for the same type of receptor. Competitors tend to resemble the natural ligand in structure.",
    "links": ["51"],
    "subtopic": "Pharmacology"
  },
  {
    "id": "62",
    "question": "MSE",
    "answer": "Calculates the average of the squared differences between predicted and actual values. It heavily penalizes larger errors due to the squaring. A lower MSE indicates better model performance.",
    "links": ["46"],
    "subtopic": "Metrics"
  },
  {
    "id": "63",
    "question": "RMSE",
    "answer": "Is the square root of the MSE. This metric is often preferred over MSE because it is in the same units as the target variable, making it easier to interpret. Like MSE, RMSE also penalizes larger errors.",
    "links": ["46"],
    "subtopic": "Metrics"
  },
  {
    "id": "64",
    "question": "MAE",
    "answer": "Calculates the average of the absolute differences between predicted and actual values. MAE is less sensitive to outliers than MSE because it doesn't square the errors. It provides a straightforward measure of the average magnitude of errors.",
    "links": ["46"],
    "subtopic": "Metrics"
  },
  {
    "id": "65",
    "question": "R^2",
    "answer": "Represents the proportion of variance in the dependent variable that is explained by the independent variables in the model. It ranges from 0 to 1, with higher values indicating a better fit. A high R² suggests that the model captures a large portion of the variability in the data.",
    "links": ["46"],
    "subtopic": "Metrics"
  },
  {
    "id": "66",
    "question": "F1",
    "answer": "Provides a balance between precision and recall. F1 = 2 * (precision * recall) / (precision + recall)",
    "links": ["47"],
    "subtopic": "Metrics"
  },
  {
    "id": "67",
    "question": "Linear Regression",
    "answer": "Predicts a line of best fit amongst continuous data.",
    "links": ["46"],
    "subtopic": "Statistics"
  },
  {
    "id": "68",
    "question": "Logistic Regression",
    "answer": "Predicts the probability of a categorical outcome (often binary).",
    "links": ["47"],
    "subtopic": "Statistics"
  }
]
